Ronan T Grimes1, Kathleen Bennett2, Lesley Tilson3, Cara Usher3, Susan M Smith4, Martin C Henman1. 1. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland. 2. Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland. 3. National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland. 4. Department of General Practice, Royal College of Surgeons Ireland, Beaux Lane House, Lower Mercer Street, Dublin, Ireland.
Abstract
AIMS: The aim was to describe the utilization of antidiabetic agents, in terms of persistence and regimen change, in the management of a cohort of newly treated type 2 diabetes patients and to investigate associated socio-demographic and treatment factors. METHODS: A population-based retrospective cohort study was conducted using the national pharmacy claims database in Ireland. Subjects were analyzed for persistence and regimen change. Cox proportional hazards regression examined associations of socio-demographic and treatment factors on treatment patterns. Hazard ratios (HR) and 95% CIs are presented. RESULTS: A total of 20947 subjects were identified in the study over a 2 year period. Most were initiated on metformin (76%) or sulphonylureas (22%) and 77% were persistent with therapy 12 months after initiation. The likelihood of non-persistence was significantly lower in the youngest (40-49 years) age groups (reference 60-69 years) (HR 1.62, 95% CI 1.42, 1.84) and those on sulphonylureas (HR 1.49, 95% CI 1.36, 1.64). The likelihood of receiving a regimen change was significantly lower in the older (80+ years) age groups (HR 0.63, 95% CI 0.56, 0.71), females (HR 0.91, 95% CI 0.86, 0.95), and those with pre-existing CVD (1 vs. 0 CVD medicines) (HR 0.82, 95% CI 0.74, 0.90), and higher in those on sulphonylureas (HR 1.83, 95% CI 1.73, 1.94). CONCLUSIONS: Type of treatment, pre-existing CVD and demographic factors are shown to be associated with the observed treatment patterns. Guideline recommended agents were widely used on treatment initiation though a substantial minority were not initiated on the recommended first line agent. Use of guideline recommended agents was not as evident during treatment progression. Further optimization of initial and subsequent antidiabetic agent prescribing may be possible.
AIMS: The aim was to describe the utilization of antidiabetic agents, in terms of persistence and regimen change, in the management of a cohort of newly treated type 2 diabetespatients and to investigate associated socio-demographic and treatment factors. METHODS: A population-based retrospective cohort study was conducted using the national pharmacy claims database in Ireland. Subjects were analyzed for persistence and regimen change. Cox proportional hazards regression examined associations of socio-demographic and treatment factors on treatment patterns. Hazard ratios (HR) and 95% CIs are presented. RESULTS: A total of 20947 subjects were identified in the study over a 2 year period. Most were initiated on metformin (76%) or sulphonylureas (22%) and 77% were persistent with therapy 12 months after initiation. The likelihood of non-persistence was significantly lower in the youngest (40-49 years) age groups (reference 60-69 years) (HR 1.62, 95% CI 1.42, 1.84) and those on sulphonylureas (HR 1.49, 95% CI 1.36, 1.64). The likelihood of receiving a regimen change was significantly lower in the older (80+ years) age groups (HR 0.63, 95% CI 0.56, 0.71), females (HR 0.91, 95% CI 0.86, 0.95), and those with pre-existing CVD (1 vs. 0 CVD medicines) (HR 0.82, 95% CI 0.74, 0.90), and higher in those on sulphonylureas (HR 1.83, 95% CI 1.73, 1.94). CONCLUSIONS: Type of treatment, pre-existing CVD and demographic factors are shown to be associated with the observed treatment patterns. Guideline recommended agents were widely used on treatment initiation though a substantial minority were not initiated on the recommended first line agent. Use of guideline recommended agents was not as evident during treatment progression. Further optimization of initial and subsequent antidiabetic agent prescribing may be possible.
Authors: Egbert J F Lamberts; Giel Nijpels; Laura M C Welschen; Jacqueline G Hugtenburg; Jacqueline M Dekker; Patrick C Souverein; Marcel L Bouvy Journal: Pharmacoepidemiol Drug Saf Date: 2010-12-23 Impact factor: 2.890
Authors: Fernie J A Penning-van Beest; Sjoukje van der Bij; Joëlle A Erkens; Sophia Kessabi; Martijn Groot; Ron M C Herings Journal: Curr Med Res Opin Date: 2008-09 Impact factor: 2.580
Authors: Kristian B Filion; Lawrence Joseph; Jean-François Boivin; Samy Suissa; James M Brophy Journal: Pharmacoepidemiol Drug Saf Date: 2009-10 Impact factor: 2.890
Authors: William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: Mary K Rhee; Kirsten Herrick; David C Ziemer; Viola Vaccarino; William S Weintraub; K M Venkat Narayan; Paul Kolm; Jennifer G Twombly; Lawrence S Phillips Journal: Diabetes Care Date: 2009-10-06 Impact factor: 19.112
Authors: David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman Journal: Diabetes Care Date: 2008-10-22 Impact factor: 17.152
Authors: S S Kumar; H McManus; T Radovich; J R Greenfield; A Viardot; K M Williams; P Cronin; R O Day Journal: Eur J Clin Pharmacol Date: 2018-06-24 Impact factor: 2.953